Breathomix, founded in 2018, is pioneering innovations in non-invasive diagnostics through its BreathBase® Solution. The company's mission is to elevate breath analysis to be as commonplace in clinical practices as blood testing, with the aim of revolutionizing early disease detection and enhancing precision medicine.
The core technology, BreathBase®, integrates an easy-to-use eNose called SpiroNose® with an AI-enhanced platform and a growing online reference database, enabling rapid, on-site analysis of exhaled biomarkers within seconds. This approach is set to address unmet medical needs across diverse disease areas, including chronic respiratory conditions, cancer, and infectious diseases.
Breathomix is strategically positioned to leverage data-driven medicine for the era of precision healthcare. Investors may find the company's innovative approach and commitment to cutting-edge medical diagnostics a compelling opportunity for advancing non-invasive health solutions.